News | Population Health | October 18, 2019

New Registry to Provide Insight into STEMI Occurrence, Treatment in North India

First prospective cohort study of this magnitude in the region already providing unique data about opportunities to improve STEMI management in India

New Registry to Provide Insight into STEMI Occurrence, Treatment in North India

Image courtesy of UNC School of Medicine

October 18, 2019 — A new study published in Clinical Cardiology[1] introduces the North Indian (NORIN) ST‐Segment Elevation Myocardial Infarction (STEMI) Registry and provides preliminary data collected since its start in January of this year. The prospective cohort study’s first author, Sameer Arora, M.D., UNC School of Medicine cardiology fellow and preventive medicine resident, says researchers will follow approximately 3,500 patients admitted for STEMI treatment to two government-funded medical centers in New Delhi, India.

These hospitals serve a large proportion of the patients with lower socioeconomic status presenting from multiple states in India, as many centers in these states lack adequate specialized cardiovascular care. The NORIN STEMI registry aims to provide important insights regarding contemporary risk factors profiles, practice patterns and prognosis in patients with STEMI in an underserved population in North India. These findings may identify opportunities to improve the outcomes of patients with STEMI in the country.

From January through March of this year, 558 patients were registered in the study. Preliminary data from those patients is already providing insight into this population that has not been available previously.

“We have found that only 14 percent of patients being treated for STEMI at these hospitals are women, which is much lower than the average number of women having this kind of heart attack in the United States,” Arora said. “We suspect 14 percent is also lower than the actual average of women having STEMI in North India, but we need to understand why more women aren’t making it to the hospital for treatment.”

Researchers have also found the average age of STEMI patients in this study is nearly ten years younger than the average age of patients in Europe and the U.S. About a third of the patients are less than 50 years old. Arora says this is exactly the kind of information that will provide more insight into population health in that region and help improve treatment for STEMI.

Throughout the course of the study, researchers will follow up with patients several times within one year of their initial treatment for STEMI. The study is currently un-funded.

For more information: www.onlinelibrary.wiley.com

Reference

1. Arora S., Qamar A., Gupta P., et al. Design and rationale of the North Indian ST-Segment Elevation Myocardial Infarction Registry: A prospective cohort study. Clinical Cardiology, published online Oct. 8, 2019. https://doi.org/10.1002/clc.23278

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Overlay Init